Cytochalasin D
(Synonyms: 细胞松弛素D; Zygosporin A; NSC 209835) 目录号 : GC13440An inhibitor of actin polymerization
Cas No.:22144-77-0
Sample solution is provided at 25 µL, 10mM.
-
Related Biological Data
Cellular internalization and localization of MoS2 nanosheets. A) Representative images of MoS2 nanosheets and brightfield were taken by confocal microscopy; B) The fluorescence intensity of FITC-BSA labeled MoS2 nanosheets was quantified by flow cytometry.
Cells were exposed to FITC-BSA labeled MoS2 nanosheets and simultaneously treated with different cellular internalization inhibitors, including Cyto D (GLPBIO, Montclair, CA, USA), Nystatin, chlorpromazine and 4-PBA.
Small, 2023: 2208063. PMID: 36908089 IF: 15.1536 -
Related Biological Data
Hydrogels with strain-enhanced stress relaxation regulate myocardin related transcription factor (MRTF) nuclear localization through the polymerization of F-actin. H) Schematics illustrating the inhibitory effect of Cyto-D on actin polymerization.
Cytochalasin (Cyto)-D (Glpbio, GC13440)
Small 20.9 (2024): 2305218. PMID: 37847903 IF: 13.3003 -
Related Biological Data
The engineered strains enhanced the activation of the STING pathway in innate immune cells, blocked by cytochalasin D. (H and I) THP1-Dual cells were pretreated with cytochalasin D (10 μM) or media for 1 h; the ratio of CIBT4523 (H) or CIBT4712 (I) to THP1-Dual cells is shown as indicated.
Additionally, to perform the cytochalasin D (GC13440, GlpBio, US) assay, these compounds (10 μM) were pretreated with the indicated cells for 1 h before each strain was added.
Research 6 (2023): 0102. PMID: 37011280 IF: 11.0003 -
Related Biological Data
Transcriptome sequencing of macrophages on different fibers.(e & f & g) Effects of addition of cytochalasin D on ATP production (e) and TNF-α (f) and IL-10 (g) secretion of macrophages.
Cytochalasin D (GLPBIO, USA) with a concentration of 0.1 μg/mL was added to the inhibition group and cultured for 24 h.
Acta Biomaterialia (2024). PMID: 38579918 IF: 9.7004 -
Related Biological Data
Confocal micrographs of MAC-T cells pretreated with or without indicated inhibitors, followed by 2 h of incubation with 20 μg/mL DiO-labeled S. aureus EVs.
Endocytosis inhibitors cytochalasin D (cyto D), methyl-β-cyclodextrin (MβCD), and dynasore were purchased from Glpbio (United States) and used at a final concentration of 2.5 μM, 4 mM, and 40 μM, respectively.
Microbiol Res (2023): 127421. IF: 5.0698 -
Related Biological Data
Isolation and evaluation of properties of M2-EVs in vitro.(E) Cells were pre-treated with DMSO, Baf-A1 (Bafilomycin A1), Cyto D (Cytochalasin D) or Wtmn (Wortmannin) for 15 min, and the incubated PKH26 labeled M2-EVs (Red) for 4 h.
To determine the cellular uptake mechanism of M2-EVs, cells were pretreated with inhibitors including Bafilomycin A1 (10 nM, Glpbio), Cytochalasin D (0.5 μM, Glpbio), and Wortmannin (0.5 μM, Glpbio) for 30 min, and then incubated with PKH26-169 labeled EVs.
bioRxiv (2022). PMID: 35792186
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
| Cell experiment [1-3]: | |
|
Cell lines |
HeLa, Vero, L, HEp2, and MDBK cells, SC-1 cells, Murine CT26 colorectal carcinoma cells |
|
Preparation method |
The solubility of this compound in DMSO is > 10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
|
Reacting condition |
0.2–0.5 μg/ml |
|
Applications |
In HeLa, Vero, L, HEp2, and MDBK cells, cytochalasin D (0.2–0.5 μg/ml) induced sustained contraction (contracture), loss of microvilli, expression of endoplasmic contents (zeiosis), nuclear protrusion, and extension of cytoplasmic processes. Cells in G1 were most sensitive to CD; responsiveness decreased progressively during early S and is least in mid S through G2. CD inhibited transport of [14C]deoxyglucose in HeLa. In SC-1 cells, Cytochalasin D treatment severely disrupted network organization, increased the number of actin filament ends, and led to the formation of filamentous aggregates or foci composed mainly of actin filaments. Cytochalasin D (0.24~15 μg/mL, 16 h) inhibited CT26 tumor cell proliferation in time and dose dependent manner and induced significant CT26 cell apoptosis. |
| Animal experiment [3,4]: | |
|
Animal models |
Murine CT26 tumor model, porcine coronary model |
|
Dosage form |
Intravenous injection, 50 mg/kg, every 3 days for 21 days |
|
Application |
Cytochalasin D (i.v., 50 mg/kg) in vivo treatment significantly inhibited tumor growth and prolonged the survival times in CT26 tumor-bearing mice. In porcine coronary model, Cytochalasin D (2 μg) resulted in less late lumen loss in low-dose. High-dose Cytochalasin D (20 μg) inhibited both late lumen loss and intimal area. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1]. Miranda A F, Godman G C, Deitch A D, et al. Action of cytochalasin D on cells of established lines[J]. The Journal of cell biology, 1974, 61(2): 481-500. [2]. Schliwa M. Action of cytochalasin D on cytoskeletal networks[J]. The Journal of cell biology, 1982, 92(1): 79-91. [3]. Huang F Y, Li Y N, Mei W L, et al. Cytochalasin D, a tropical fungal metabolite, inhibits CT26 tumor growth and angiogenesis[J]. Asian Pacific journal of tropical medicine, 2012, 5(3): 169-174. [4].Salu K J, Bosmans J M, Huang Y, et al. Effects of cytochalasin D-eluting stents on intimal hyperplasia in a porcine coronary artery model[J]. Cardiovascular research, 2006, 69(2): 536-544. |
|
The cytochalasins are cell-permeable fungal metabolites that inhibit actin polymerization.[1],[2],[3],[4] This interferes with such diverse processes as cell movement, growth, phagocytosis, degranulation, and secretion.[5],[6],[7],[8] Cytochalasin D is a cell-permeable inhibitor that binds actin filaments, but not actin monomers, to inhibit polymerization at concentrations as low as 0.2 µM.2 In this way, it prevents the migration of tumor cells.[9]
Reference:
[1]. Brenner, S.L., and Korn, E.D. The effects of cytochalasins on actin polymerization and actin ATPase provide insights into the mechanism of polymerization. The Journal of Biological Chemisty 255(3), 841-844 (1980).
[2]. Lin, D.C., Tobin, K.D., Grumet, M., et al. Cytochalasins inhibit nuclei-induced actin polymerization by blocking filament elongation. Journal of Cell Biology 84, 455-460 (1980).
[3]. Ostlund, R.E., Jr., Leung, J.T., and Hajek, S.V. Regulation of microtubule assembly in cultured fibroblasts. Journal of Cell Biology 85, 386-391 (1980).
[4]. Pinder, J.C., and Gratzer, W.B. Structural and dynamic states of actin in the erythrocyte. Journal of Cell Biology 96(3), 768-775 (1983).
[5]. Flaumenhaft, R., Dilks, J.R., Rozenvayn, N., et al. The actin cytoskeleton differentially regulates platelet α-granule and dense-granule secretion. Blood 105(10), 3879-3887 (2005).
[6]. Taheri-Talesh, N., Horio, T., Araujo-Bazán, L., et al. The tip growth apparatus of Aspergillus nidulans. Molecular Biology of the Cell 19, 1439-1449 (2008).
[7]. dos Santos, T., Varela, J., Lynch, I., et al. Effects of transport inhibitors on the cellular uptake of carboxylated polystyrene nanoparticles in different cell lines. PLoS One 6(9), 1-10 (2011).
[8]. Nightingale, T.D., White, I.J., Doyle, E.L., et al. Actomyosin II contractility expels von Willebrand factor from Weibel-Palade bodies during exocytosis. Journal of Cell Biology 194(4), 613-629 (2011).
[9]. Hayot, C., Debeir, O., Van Ham, P., et al. Characterization of the activities of actin-affecting drugs on tumor cell migration. Toxicology and Applied Pharmacology 211, 30-40 (2006).
细胞毒霉素是一种可渗透进入细胞的真菌代谢产物，可以抑制肌动蛋白聚合。这会干扰诸如细胞运动、生长、吞噬作用、颗粒释放和分泌等多种过程。其中，细胞毒霉素D是一种可渗透进入细胞的抑制剂，它能够结合肌动蛋白丝而不是单体肌动蛋白，在低至0.2微米的浓度下抑制聚合反应。通过这种方式，它可以阻止肿瘤细胞的迁移。
| Cas No. | 22144-77-0 | SDF | |
| 别名 | 细胞松弛素D; Zygosporin A; NSC 209835 | ||
| 化学名 | (3S,3aR,4R,6R,6aS,7E,10R,12S,13Z,15R,15aS)-3-benzyl-6,12-dihydroxy-4,10,12-trimethyl-5-methylene-1,11-dioxo-2,3,3a,4,5,6,6a,9,10,11,12,15-dodecahydro-1H-cycloundeca[d]isoindol-15-yl acetate | ||
| Canonical SMILES | O[C@@H]1[C@@H](/C=C/C[C@@H](C)C2=O)[C@]3([C@@H](C=C[C@]2(C)O)OC(C)=O)[C@@H]([C@@H](C)C1=C)[C@H](CC4=CC=CC=C4)NC3=O | ||
| 分子式 | C30H37NO6 | 分子量 | 507.63 |
| 溶解度 | 10mg/mL in dichloromethane,100 mg/ml in DMSO | 储存条件 | Store at -20°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.9699 mL | 9.8497 mL | 19.6994 mL |
| 5 mM | 0.394 mL | 1.9699 mL | 3.9399 mL |
| 10 mM | 0.197 mL | 0.985 mL | 1.9699 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。